Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
| العنوان: | Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer |
|---|---|
| المؤلفون: | Guenther G. Steger, Anitra Fielding, Nigel Baker, Patricia A. Ganz, Norman Wolmark, Joseph P. Costantino, Barbro Linderholm, Larissa A. Korde, Robin McConnell, Jennifer Marie Suga, Susan M. Domchek, Karen A. Gelmon, Greg Yothers, Amal Arahmani, Richard D. Gelber, Sibylle Loibl, Hanna Bandos, Elżbieta Senkus, Giuseppe Viale, Debora Fumagalli, Judy Garber, Judith Balmaña, Christine Campbell, Sunil R. Lakhani, Vassiliki Karantza, Tomasz Huzarski, Zbigniew Nowecki, Andrew W. Pippas, Simon J. Hollingsworth, Peter Lucas, Eleanor McFadden, Zhimin Shao, Rita K. Schmutzler, Charles E. Geyer, Priya Rastogi, Bella Kaufman, Andrew Tutt, Evandro de Azambuja, Martine Piccart |
| المصدر: | New England Journal of Medicine, 384(25), 2394-2405. MASSACHUSETTS MEDICAL SOC The New England journal of medicine, vol 384, iss 25 |
| بيانات النشر: | Massachusetts Medical Society, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_treatment, Synthetic lethality, Medical and Health Sciences, Poly (ADP-Ribose) Polymerase Inhibitor, Piperazines, chemistry.chemical_compound, ErbB-2, Adjuvant, Mastectomy, Polymerase, Cancer, biology, General Medicine, Middle Aged, 6.1 Pharmaceuticals, Female, Receptor, Adult, Clinical Trials and Supportive Activities, Breast Neoplasms, Antineoplastic Agents, Poly(ADP-ribose) Polymerase Inhibitors, Disease-Free Survival, Olaparib, Breast cancer, Double-Blind Method, Clinical Research, General & Internal Medicine, Breast Cancer, medicine, Humans, Chemotherapy, Germ-Line Mutation, business.industry, Evaluation of treatments and therapeutic interventions, BRCA1, medicine.disease, BRCA2, Good Health and Well Being, Genes, chemistry, biology.protein, Cancer research, Phthalazines, Digestive Diseases, Homologous recombination, business, OlympiA Clinical Trial Steering Committee and Investigators |
| الوصف: | BackgroundPoly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer.MethodsWe conducted a phase 3, double-blind, randomized trial involving patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors who had received local treatment and neoadjuvant or adjuvant chemotherapy. Patients were randomly assigned (in a 1:1 ratio) to 1 year of oral olaparib or placebo. The primary end point was invasive disease-free survival.ResultsA total of 1836 patients underwent randomization. At a prespecified event-driven interim analysis with a median follow-up of 2.5 years, the 3-year invasive disease-free survival was 85.9% in the olaparib group and 77.1% in the placebo group (difference, 8.8 percentage points; 95% confidence interval [CI], 4.5 to 13.0; hazard ratio for invasive disease or death, 0.58; 99.5% CI, 0.41 to 0.82; P |
| وصف الملف: | application/pdf |
| تدمد: | 1533-4406 0028-4793 |
| DOI: | 10.1056/nejmoa2105215 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05e52f9a2de90257dee369f76dcfb6c2 https://doi.org/10.1056/nejmoa2105215 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....05e52f9a2de90257dee369f76dcfb6c2 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15334406 00284793 |
|---|---|
| DOI: | 10.1056/nejmoa2105215 |